Dyne Therapeutics Inc. (DYN) receives a Strong buy rating from Raymond James


Dyne Therapeutics Inc.’s recent filing unveils that its insider Scalzo Richard William unloaded Company’s shares for reported $0.12 million on Jun 15. In the deal valued at $12.03 per share,10,000 shares were sold. As a result of this transaction, Scalzo Richard William now holds 43,482 shares worth roughly $ 0.51 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, Scalzo Richard William sold 41,390 shares, generating $532,878 in total proceeds. Upon selling the shares at $12.87, the insider now owns 53,482 shares.

Before that, Farwell Wildon sold 1,698 shares. Dyne Therapeutics Inc. shares valued at $21,106 were divested by the Chief Medical Officer at a price of $12.43 per share. As a result of the transaction, Farwell Wildon now holds 90,957 shares, worth roughly $1.07 million.

Raymond James upgraded its Dyne Therapeutics Inc. [DYN] rating to a Strong buy from a an Outperform in a research note published on Friday, February 27, 2023; the price target was increased to $27 from $16. PT values the company’s stock at a premium of 56.41 to its Friday closing price.

Price Performance Review of DYN

On Friday, Dyne Therapeutics Inc. [NASDAQ:DYN] saw its stock jump 3.25% to $11.77. On the same session, the stock had its day’s lowest price of $11.27, but rose to a high of $11.84. Over the last five days, the stock has lost -1.01%. Dyne Therapeutics Inc. shares have risen nearly 1.55% since the year began. Nevertheless, the stocks have risen 20.10% over the past one year. While a 52-week high of $15.63 was reached on 03/06/23, a 52-week low of $8.04 was recorded on 04/11/23. SMA at 50 days reached $11.11, while 200 days put it at $11.99. A total of 0.24 million shares were traded, compared to the trading of 0.26 million shares in the previous session.

Levels Of Support And Resistance For DYN Stock

The 24-hour chart illustrates a support level at 11.41, which if violated will result in even more drops to 11.06. On the upside, there is a resistance level at 11.98. A further resistance level may holdings at 12.20. The Relative Strength Index (RSI) on the 14-day chart is 55.88, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.44, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 33.33%. Stochastics %K at 63.61% indicates the stock is a holding.

How much short interest is there in Dyne Therapeutics Inc.?

A steep rise in short interest was recorded in Dyne Therapeutics Inc. stocks on Aug 14, 2023, growing by 0.28 million shares to a total of 5.7 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 5.42 million shares. There was a rise of 4.91%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 12.74% of the overall stock float, the days-to-cover ratio (short ratio) rose to 16.39.

Dyne Therapeutics Inc. [DYN] – Who Are The Largest Shareholders?

In filings from BlackRock Fund Advisors, it is revealed that the company now owns 2,833,181 shares, or roughly 4.64% of the outstanding DYN shares. In other words, the investor’s shares have risen by 617,282 from its previous 13-F filing of 2215899.0. Additionally, Citadel Advisors LLC decreased -9.52% of its stake after which the total value it holdings stand at $32,959,117, while Deep Track Capital LP added 7.08% of its stake to hold $30.45 million in the firm. Over the last quarter, The Vanguard Group, Inc. purchased 916,834 shares of Dyne Therapeutics Inc., while Wasatch Advisors, Inc. bought -667,743 shares. At present, Franklin Advisers, Inc. is holding 1,895,579 shares valued at $23.09 million. Goldman Sachs & Co. LLC owned 1,879,615 shares of the company at the time of its most recent 13F filing, worth $22.89 million.

According to FactSet, Dyne Therapeutics Inc.’s share price will average $29.50 in the next year, based on opinions of analysts polled by the firm. This is up nearly 145.61 percent from its previous closing price of $11.40. Analysts expect Dyne Therapeutics Inc. stock to reach the higher price of $47.00, while the lowest price estimate is $20.00. However, 8 analysts have rated DYN stock as a Buy in their predictions for 2023.


Please enter your comment!
Please enter your name here